Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Corporate Update (October 2024)
9 slides from Halozyme Therapeutics's corporate update, Oct 24, 2024
Slide 1: Halozyme Therapeutics, Inc. Investor Update
Halozyme Therapeutics, Inc. Investor Update NASDAQ: HALO October 24, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements In addition to historical information, the statements set forth in this "enable," "may," "will," "could," “can,” “durable,” “growth,” “innovate,” presentation include forward-looking statements including, without “develop,” “vision,” “potential,” "intends," "estimate," "an
Slide 3: Agenda
Agenda Janssen European Patent Opposition Proceedings Halozyme’s Patent Portfolio Update Question & Answer Session 2
Slide 4: Janssen European Patent Opposition – Takeaways
Janssen European Patent Opposition – Takeaways Maintaining projected royalties for sales of DARZALEX® SC in Europe into 2032 Maintaining projected royalties for DARZALEX FASPRO® in the United States No impact to patentability standard and expectations for future collaboration patents 3
Slide 5: Janssen European and U.S. Collaboration Patents
Janssen European and U.S. Collaboration Patents European Collaboration Patents EP 3 370 770 Granted Patent Opposition Appeal 5/6/25 EP 3 827 845 Granted Patent Opposition Appealable EP 4 085 929 Published Application Not Granted/No Opposition U.S. Granted Collaboration Patents US 10,385,135 US 11,56
Slide 6: DARZALEX SC and DARZALEX FASPRO – Projected Royalty Term and Rate
DARZALEX® SC and DARZALEX FASPRO® – Projected Royalty Term and Rate Unchanged Product Name Co-formulation Patent Status First & Anticipated Impact Commercial Sale 2024 2027 2030 2032 Granted; royalty 12 years post first commercial DARZALEX® SC (OUS)^ sale Granted; royalty 12 years post first commerc
Slide 7: Collaboration Patents Expected from Licensee Collaborations
Collaboration Patents Expected from Licensee Collaborations Collaboration patents Patents are granted for innovations that are cover the licensed product, including: "non-obvious" or when there • Product formulations are “non-obvious” results including: • Product dosing schedules • Improved pharmaco
Slide 8: Introducing Halozyme's MDASE Patents
Introducing Halozyme’s MDASETM Patents MDASETM patents broadly cover modified human hyaluronidases for potential use in enabling subcutaneous delivery of drugs and biologics Separate patents New distinct from potential ENHANZE® patents & not MDASETM licensing Patent Portfolio opportunity included in
Slide 9: Halozyme's MDASE Patent Portfolio – Extensive Portfolio
Halozyme’s MDASETM Patent Portfolio – Extensive Portfolio Result of groundbreaking R&D by Halozyme over many years – making thousands of modifications to human hyaluronidases and characterizing the effects on stability and activity 99 Patents or pending patent applications worldwide Exclusivity1 thr
Halozyme Therapeutics — Corporate Update (October 2024) on 6ix